Indication*

Prevention of VTE in adults who have undergone elective hip or knee replacement surgery. Reduced the risk of stroke, systemic embolism, & death in patients with nonvalvular atrial fibrillation (NVAF) with >1 risk factors, including patients unsuitable for warfarin. Treatment & prevention (recurrent ) of DVT & pulmonary embolism (PE).

Directions for Use*

Prevention of VTE in elective hip or knee replacement surgery 2.5mg bid. Initial dose should be taken 12-24 hour after surgery. Recommended duration of treatment: 32-38 days for hip replacement surgery. Prevention of stroke & systemic embolism Patient with NVAF 5mg bid. Patient with at least 2 of the following characteristics: >80 year, <60kg, or serum creatinine >1.5mg/dL (133 mmoI/L) 2.5mg bid. DVT & PE 10mg bid for days, followed by 5mg bid. Prevention of recurrent DVT & PE 2.5mg bid after at least 6 month of treatment for DVT or PE. Surgery & invasive procedures Patients not previously treated with anticoagulants At least 5 doses of 5 mg bid (2.5mg bid in patient who quality for dose reduction) should be given before cardioversion to ensure adequate anticoagulation. If cardioversion is required before 5 doses of Eliquis: 10mg loading dose, followed by 5 mf bid. Reduce to 5mg loading dose, followed by 2.5mg bid if the patients meets the criteria for dose reduction. Loading dose should be given at least 2 hour before cardioversion.

Administration*

May be taken with or without food: For patients with swallowing difficulties, crush tab & suspend in water , 5% dextrose in water (D5W), apple juice or mixed with applesauce. Drink immediately. SoIn stable for 4 hour. Alternatively, crush & suspend in 60 mL water or D5W & administer via nasogastric tube.

*written indications, directions, and administration are updated as of May 10, 2024 and may not be accurate with the actual product purchased. Please read the details in the packaging.

Share

Share

Link

Close share Copy link

View full details